Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Parkinson's disease
cannabidiol
cannabis
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
revised:
14
11
2023
received:
28
08
2023
accepted:
07
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks. The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) to provide preliminary data for a longer trial. Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) who had negative cannabis testing took cannabis extract (National Institute of Drug Abuse) oral sesame oil solution for 2 weeks, increasing to final dose of 2.5 mg/kg/day. Primary outcome was change in motor MDS-UPDRS from baseline to final dose. Participants were randomized to CBD/THC (n = 31) or placebo (n = 30). Mean final dose (CBD/THC group) was 191.8 ± 48.9 mg CBD and 6.4 ± 1.6 mg THC daily. Motor MDS-UPDRS was reduced by 4.57 (95% CI, -8.11 to -1.03; P = 0.013) in CBD/THC group, and 2.77 (-4.92 to -0.61; P = 0.014) in placebo; the difference between groups was non-significant: -1.80 (-5.88 to 2.27; P = 0.379). Several assessments had a strong placebo response. Sleep, cognition, and activities of daily living showed a treatment effect, favoring placebo. Overall adverse events were mild and reported more in CBD/THC than placebo group. On 2.5 mg/kg/day CBD plasma level was 54.0 ± 33.8 ng/mL; THC 1.06 ± 0.91 ng/mL. The brief duration and strong placebo response limits interpretation of effects, but there was no benefit, perhaps worsened cognition and sleep, and there was many mild adverse events. Longer duration high quality trials that monitor cannabinoid concentrations are essential and would require improved availability of research cannabinoid products in the United States. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks.
OBJECTIVE
OBJECTIVE
The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) to provide preliminary data for a longer trial.
METHODS
METHODS
Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) who had negative cannabis testing took cannabis extract (National Institute of Drug Abuse) oral sesame oil solution for 2 weeks, increasing to final dose of 2.5 mg/kg/day. Primary outcome was change in motor MDS-UPDRS from baseline to final dose.
RESULTS
RESULTS
Participants were randomized to CBD/THC (n = 31) or placebo (n = 30). Mean final dose (CBD/THC group) was 191.8 ± 48.9 mg CBD and 6.4 ± 1.6 mg THC daily. Motor MDS-UPDRS was reduced by 4.57 (95% CI, -8.11 to -1.03; P = 0.013) in CBD/THC group, and 2.77 (-4.92 to -0.61; P = 0.014) in placebo; the difference between groups was non-significant: -1.80 (-5.88 to 2.27; P = 0.379). Several assessments had a strong placebo response. Sleep, cognition, and activities of daily living showed a treatment effect, favoring placebo. Overall adverse events were mild and reported more in CBD/THC than placebo group. On 2.5 mg/kg/day CBD plasma level was 54.0 ± 33.8 ng/mL; THC 1.06 ± 0.91 ng/mL.
CONCLUSIONS
CONCLUSIONS
The brief duration and strong placebo response limits interpretation of effects, but there was no benefit, perhaps worsened cognition and sleep, and there was many mild adverse events. Longer duration high quality trials that monitor cannabinoid concentrations are essential and would require improved availability of research cannabinoid products in the United States. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Colorado Department of Public Health and Environment Medical marijuana research grant program, contract
Informations de copyright
© 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Holden SK, Domen CH, Sillau S, Liu Y, Leehey MA. Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson's disease. Mov Disord Clin Pract 2022;9:340-350.
Yenilmez F, Fründt O, Hidding U, Buhmann C. Cannabis in Parkinson's disease: the Patients' view. J Parkinsons Dis 2021;11:309-321.
Oikonomou P, Jost WH. Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. J Neural Transm (Vienna) 2022;129:1247-1256.
Urbi B, Corbett J, Hughes I, et al. Effects of cannabis in Parkinson's disease: a systematic review and meta-analysis. J Parkinsons Dis 2022;12:495-508.
Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry 2020;7:344-353.
de Faria SM, de Morais FD, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson's disease. J Psychopharmacol 2020;34:189-196.
Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol 2014;28:1088-1098.
Leehey MA, Liu Y, Hart F, et al. Safety and tolerability of Cannabidiol in Parkinson disease: an open label, dose-escalation study. Cannabis Cannabinoid Res 2020;5:326-336.
de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord 2021;36:1711-1715.
Feeney MP, Bega D, Kluger BM, et al. Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. NPJ Parkinsons Dis 2021;7:21.
Chagas MHN, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 2014;39:564-566.
Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res 2019;8:F1000.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-1028.
Klawitter J, Sempio C, Morlein S, et al. An atmospheric pressure chemical ionization MS/MS assay using online extraction for the analysis of 11 cannabinoids and metabolites in human plasma and urine. Ther Drug Monit 2017;39:556-564.
Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified Cannabidiol in healthy subjects. CNS Drugs 2018;32:1053-1067.
Domen CH, Sillau S, Liu Y, et al. Cognitive safety data from a randomized, double-blind, parallel-group, placebo-controlled phase IIb study of the effects of a Cannabidiol and Delta9-tetrahydrocannabinol drug on Parkinson's disease-related motor symptoms. Mov Disord 2023;38:1341-1346.
Domen CH, Sillau S, Liu Y, Leehey M. Reply to: cognitive safety of cannabis products in Parkinson's disease: need for solid scientific evidence to guide clinicians and patients currently on shaky grounds. Mov Disord 2024;39:222-223.
Horváth K, Aschermann Z, Ács P, et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord 2015;21:1421-1426.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22:1901-1911.
Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson M, eds. Third Symposium on Parkinson's Disease. Edinburgh: E. and S. Livingstone; 1969:152-157.
Goetz CG, Nutt JG, Stebbins GT. The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 2008;23:2398-2403.
Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 2012;78:1860-1867.
Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010;63:1179-1194.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
Morin CM, Belleville G, Bélanger L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 2011;34:601-608.
Walters AS, LeBrocq C, Dhar A, et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431-436.
Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Revised National Institute of Mental Health; 1976.
Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health 2014;17:445-453.
Blaivas JG, Panagopoulos G, Weiss JP, Somaroo C. Validation of the overactive bladder symptom score. J Urol 2007;178:543-547. discussion 547.
Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale. Mov Disord 2012;27:242-247.
Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-1250.
Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 2004;27:108-110.
Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
Peball M, Krismer F, Knaus HG, et al. Non-motor symptoms in Parkinson's disease are reduced by Nabilone. Ann Neurol 2020;88:712-722.
Di Luca DG, Gilmour GS, Fearon C, et al. A phase Ib, double blind, randomized study of cannabis oil for pain in Parkinson's disease. Mov Disord Clin Pract 2023;10:1114-1119.
Urits I, Gress K, Charipova K, et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol 2020;34:463-477.
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456-2473.
Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985;35:291-295.
Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D. The placebo response in Parkinson's disease. Int Rev Neurobiol 1999;22:207-212.
Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710-714.
de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (New York, NY) 2001;293:1164-1166.
de la Fuente-Fernández R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-306.
Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: what we have learned and where we are going. Mov Disord 2018;33:1213-1227.
Evans K, Colloca L, Pecina M, Katz N. What can be done to control the placebo response in clinical trials? A narrative review. Contemp Clin Trials 2021;107:106503.
Lee S, Walker JR, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004;19:10-19.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol 2019;17:974-989.
Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005;22:679-680.
Horváth, K, Aschermann, Z, Ács, P, et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Park & Reld Dis, 2015; 21: 1421-1426.
Shulman, LM, Gruber-Baldini, AL. Anderson, KE, Fishman, PS, Reich, SG, Weiner, WJ. The Clinically Important Difference on the Unified Parkinson’s Disease Rating Scale. Arch of Neurol 2010;67: 64-70.